Form 4 Mylan N.V. For: Feb 05 Filed by: Campbell Paul
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Mylan (MYL) Misses Q4 EPS by 5c
February 10, 2016 4:13 PM ESTMylan (NASDAQ: MYL) reported Q4 EPS of $1.22, $0.05 worse than the analyst estimate of $1.27. Revenue for the quarter came in at $2.49 billion versus the consensus estimate of $2.7 billion.
GUIDANCE:
Mylan sees FY2016 EPS of $4.85-$5.15, versus the consensus of $4.90.
For earnings history and earnings-related data on Mylan (MYL) click here.
... MoreMylan (MYL) Enters Agreement to Acquire Meda in ~$9.9B Deal
February 10, 2016 4:03 PM ESTPrice of SEK 165 per Meda Share at Announcement Represents a Multiple of Approximately 12.9x 2015 Adjusted EBITDA and 8.9x 2015 Adjusted EBITDA with Synergies
Strengthens Mylan's Position as a Diversified Global Pharmaceutical Leader with an Expansive and Growing Portfolio of Specialty, Generic and OTC Products and a Strong, Complementary Therapeutic Presence
Combined Business Will Have Critical Mass across Commercial Channels in Europe, a Leading U.S. Specialty Business, and an Exciting Platform for Growth in Emerging Markets
Expected to Be Immediately Accretive to Mylan Earnings, with Accretion Increasing Significantly after First Full Year (2017) as Synergies Are Realized; Creates... More
